Outlook Therapeutics, Inc. Stock

$1.86

4.49%

Nasdaq, Jul 07, 10:00 pm CET

ISIN

US69012T2069

Symbol

OTLK

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Outlook Therapeutics, Inc. Stock price

$1.86

-24.34 92.90% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

+0.08 4.49%

ISIN

US69012T2069

Symbol

OTLK

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$76.3m

Enterprise Value

$101.8m

Net debt

$25.5m

Cash

$7.6m

Shares outstanding

32.9m

Valuation (TTM | estimate)

P/E

2.7 | negative

P/S

- | 10.3

EV/Sales

- | 13.7

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-251.7%

Return on Equity

102.7%

ROCE

1,339.3%

ROIC

-5,779.4%

Debt/Equity

-1.0

Financials (TTM | estimate)

Revenue

$0.0 | $7.4m

EBITDA

$-76.8m | -

EBIT

$-76.9m | $-63.5m

Net Income

$20.7m | $-46.1m

Free Cash Flow

$-64.1m

EPS

$0.7

FCF per Share

$-1.9

Short interest

7.8%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Outlook Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Outlook Therapeutics, Inc. forecast:

9x Buy

82%

2x Hold

18%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Outlook Therapeutics, Inc. forecast:

Buy

82%

Hold

18%

Analyst Estimates with Stock Price Targets

Financial data from Outlook Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	39 39	50% 50% -
- Research and Development Expense	38 38	11% 11% -
EBITDA	-77 -77	28% 28% -
- Depreciation and Amortization	0.12 0.12	50% 50% -
EBIT (Operating Income) EBIT	-77 -77	28% 28% -
Net Profit	21 21	113% 113% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Outlook Therapeutics, Inc. Stock News

Neutral

GlobeNewsWire

●

6 days ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies

Neutral

GlobeNewsWire

●

19 days ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a Virtual Investor Lunch Break Event on Wednesday, June 25, 2025 at 12:00 PM ET.

Neutral

GlobeNewsWire

●

27 days ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degenerat...

More Outlook Therapeutics, Inc. News

Company Profile

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.

Head office	United States
CEO	Lawrence Kenyon
Employees	23
Founded	2010
Website	outlooktherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now